Kalaris Therapeutics names Laurie Keating to its board

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) announced the appointment of Laurie Keating to its board of directors, effective August 1, 2026, according to a press release. Concurrently, board member Morana Jovan-Embiricos is stepping down.

Keating currently serves as chair of the board of PepGen (Nasdaq: PEPG) and as a board member of Immuneering Corp (Nasdaq: IMRX). She previously served on the boards of Imago Biosciences, which was acquired by Merck, Imbria Pharmaceuticals, and the Massachusetts Biotechnology Council.

Keating formerly held the role of Executive Vice President, General Counsel and Corporate Secretary at Alnylam Pharmaceuticals, where she oversaw global government affairs, legal, intellectual property, litigation, and compliance functions. Prior to that, she served as SVP, General Counsel and Corporate Secretary at Millennium Pharmaceuticals, which was later acquired by Takeda Pharmaceuticals.

She holds a bachelor's degree in economics from the University of California, Berkeley, and a JD from the University of California, Hastings College of the Law.

David Hallal, chairman of the Kalaris board, thanked the departing member in a statement: "I also want to thank Morana for her service to Kalaris over the past year. She was a valuable member of our Board and helped us make significant advances in the development of TH103 and in our evolution as a public biotech company."

Kalaris is a clinical-stage biopharmaceutical company focused on treatments for retinal diseases, with its lead candidate TH103 currently in a Phase 1b/2 clinical trial for neovascular age-related macular degeneration.

You May Also Be Interested In

• Western Union chief legal officer to retire in November 2026
• United Therapeutics adds former NAM president Victor Dzau to its board
• Longeveron adds Dr. Deborah Ascheim to its board of directors